Please assess the completion status of the following clinical trial:

Trial Title: Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Have a documented active COVID-19 infection and one of the following high-risk criteria:~* Malignancy receiving radiation or chemotherapy in the prior 24 months.~* Chronic lung disease such as asthma, COPD, interstitial lung disease, pulmonary hypertension or cystic fibrosis, requiring treatment beyond inhaled medications~* Hypertension either treated or with evidence of need for treatment~* Cardiovascular disease requiring active medical monitoring and care including heart failure, heart dysrhythmias, coronary artery disease, congenital heart disease, cardiomyopathy, or pulmonary hypertension~* History of ischemic stroke~* Diabetes (type 1, type 2, or gestational) requiring treatment with insulin or oral hypoglycemics~* Chronic Kidney Disease (Hx of stage 3b or greater as defined by the National Kidney Foundation)~* Chronic Liver Disease (Previously diagnosed with cirrhosis or previously classified as having Pugh-Child class A-C liver disease) oObesity (BMI \>= 35) oSickle Cell Disease or Thalassemia~* Patients requiring nursing home support or who have a Karnofsky Performance Status of 70% or less antedating their COVID-19 illness.~* Age \>= 65 (with or without previously identified comorbid conditions)~Exclusion Criteria:~* Matching their intended CTL product donor at 5 or 6 of 6 HLA-class I (HLA-A, B, and C) alleles.~* Requiring supplemental oxygen~* Evidence of active COVID-19-related CRS as evidenced by 2 or more of the following characteristics of cytokine storm:~  o\> grade 1 CRS on ASTCT criteria. ASTCT criteria do not provide quantitative guidelines regarding the definition of hypotension. For this trial, hypotension will be defined as:~ 1. requiring vasopressors~ 2. Systolic blood pressure \<90 mm Hg~ 3. Diastolic B/P \< 60 mm Hg NB Lower systolic and diastolic blood pressures will be acceptable if patient's blood pressure is at his/her known baseline.~     * Uncontrolled hypertension as defined by a systolic pressure of \> 180 mm Hg or diastolic pressure \> 100 mm Hg. A second blood pressure reading may be obtained by study personnel to assure blood pressure accuracy.~    * radiographic studies consistent with adult respiratory distress syndrome~    * Patients requiring acute dialysis~    * hyperferritinemia as defined by ferritin \> 2000 ng/mL 55~    * Concurrent treatment with \>5 mg of prednisone daily (or equivalent).~* Current or ongoing administration of calcineurin inhibitors, chemotherapy, radiation, or other immunosuppressive agents.~  * That cannot be held for 14 days after CTL infusion~ * That would not decay 3 1/2 half-lives by the day of CTL infusion using longest published half-life.~* Receipt of agents with ongoing immunosuppressive properties in the last 30 days including, ATG, Alemtuzumab, or similar agents.~* Prior allogeneic bone marrow, stem cell, or solid organ transplant. Patients with a history of autologous transplant are eligible for study if one year has elapsed since their transplant.~* Active HIV infection with CD4 count less than 200/ul.~* Pregnancy (lactating females allowable)~* Concomitant treatment with another experimental intervention for COVID-19 other than Remdesivir.~* History of allergic reaction to cellular therapy products (includes blood transfusion), diphenhydramine, or tocilizumb~* Corrected QT interval \> 450 milliseconds~* History of torsade de pointes or other ventricular arrhythmia Women of childbearing potential, and partners of women of childbearing potential should be using at least one method of highly effective contraception at the time of enrollment and for the 14-day duration of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARM A: Covid-19 Patients Receiving CTLs (Type: EXPERIMENTAL): Patients who have an HLA antigen in common with COVID-19 fighting T cells will receive the COVID-19 T cells. They will be premedicated with diphenhydramine and acetaminophen before the cells are infused intravenously. Close monitoring will continue in the patients' homes for 14 days. Three to six patients will receive a specific dose of T cells, and then if there are no serious side effects, the dose will be increased for the next group of patients. There are 4 doses of T cells to be tested, and each patient will complete a 14 day monitoring period before the next patient can be treated.
- ARM B: Covid-19 Patients Not Receiving CTLs (Type: NO_INTERVENTION): Patients in the observation arm will not have inherited an HLA antigen in common with the COVID-19 T cells and so cannot receive the T cells. They will be monitored by the study staff for the 14 day monitoring period in their homes. They will be taught to record their own blood pressure, temperature, and oxygen level (pulse oximetry) at home and report this information, as well as their progress in getting over the COVID-19 infection, to the study staff every day by phone. The outcomes of patients on arm B will be compared to the outcomes of patients treated on Arm A to see if the T cells made a difference in how patients recovered from COVID-19. Patients in Arm B are not prevented from being treated with any available COVID-19 therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).